Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.2% - Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s share price rose 7.2% during trading on Friday . The stock traded as high as $10.95 and last traded at $10.92. Approximately 646,594 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 1,962,038 shares. The stock had previously closed at $10.18.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research reports. Roth Capital reissued a "buy" rating and issued a $31.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. Oppenheimer decreased their price objective on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a report on Monday. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Tuesday. Finally, Jones Trading decreased their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $33.75.

Capricor Therapeutics Stock Up 9.8%

The stock has a market capitalization of $510.44 million, a price-to-earnings ratio of -7.87 and a beta of 0.84. The company has a fifty day moving average of $10.89 and a two-hundred day moving average of $12.38.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same period in the previous year, the firm earned ($0.31) EPS. Equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of the business. Summit Investment Advisors Inc. lifted its holdings in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 1,345 shares during the period. Russell Investments Group Ltd. increased its position in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter worth about $68,000. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund increased its stake in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 5,000 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.